ω-6 Polyunsaturated fatty acids extend life span through the activation of autophagy

Eyleen J. O’Rourke,1,2 Petric Kuballa,3,4 Ramnik Xavier,3,4 and Gary Ruvkun1,2,5

1Department of Molecular Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA; 2Department of Genetics, Harvard Medical School, Boston, Massachusetts 02114, USA; 3Gastrointestinal Unit, 4Center for Computational and Integrative Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA

Adaptation to nutrient scarcity depends on the activation of metabolic programs to efficiently use internal reserves of energy. Activation of these programs in abundant food regimens can extend life span. However, the common molecular and metabolic changes that promote adaptation to nutritional stress and extend life span are mostly unknown. Here we present a response to fasting, enrichment of ω-6 polyunsaturated fatty acids (PUFAs), which promotes starvation resistance and extends C. elegans life span. Upon fasting, C. elegans induces the expression of a lipase, which in turn leads to an enrichment of ω-6 PUFAs. Supplementing C. elegans culture media with these ω-6 PUFAs increases their resistance to starvation and extends their life span in conditions of food abundance. Supplementation of C. elegans or human epithelial cells with these ω-6 PUFAs activates autophagy, a cell recycling mechanism that promotes starvation survival and slows aging. Inactivation of C. elegans autophagy components reverses the increase in life span conferred by supplementing the C. elegans diet with these fasting-enriched ω-6 PUFAs. We propose that the salubrious effects of dietary supplementation with ω-3/6 PUFAs (fish oils) that have emerged from epidemiological studies in humans may be due to a similar activation of autophagic programs.

[Keywords: C. elegans; fasting; lipid; autophagy; polyunsaturated fatty acids (PUFA); longevity]

Supplemental material is available for this article.

Received September 7, 2012; revised version accepted January 10, 2013.
mechanism that promotes starvation survival. In addition to being a major response to caloric restriction, autophagy can slow aging and the onset of age-related disorders (Cuervo 2008; Rubinsztein et al. 2011). We show that dietary supplementation with these fasting-enriched ω-6 PUFAs increases *C. elegans* life span in well-fed animals by activating autophagy. We also show that the ability to respond to ω-6 PUFAs by activating autophagy is conserved in mammalian cells. Hence, our results reveal that ω-6 PUFAs act as a link between lipolysis and life span in *C. elegans* and suggest that these ω-6 PUFAs activate responses normally occurring in calorically restricted animals across metazoans.

**Results**

**ω-6 PUFAs enriched upon fasting increase C. elegans resistance to starvation**

The *C. elegans* lipase gene *lipl-4* is induced in germline-deficient mutants and is necessary for the increased longevity of these animals [Wang et al. 2008]. A *Drosophila* homolog, Lip3, is the most up-regulated gene in glucose-deprived *Drosophila* (Zinke et al. 2002). We tested whether *lipl-4* is responsive to nutritional stress in *C. elegans* and found that it is transcriptionally up-regulated up to seven-fold in fertile adults fasted for 2, 6, or 12 h relative to ad libitum-fed age-matched animals [Fig. 1A]. However, despite its strong response to fasting and its predicted role as a triglyceride lipase, *lipl-4* deficiency [*lipl-4(tm4417)*] does not affect lipid levels in ad libitum-fed or fasted worms (Supplemental Fig. S1A). One likely explanation for the lack of a lipid phenotype in the *lipl-4* knockout mutant is redundancy: *lipl-4* is one member of a family of *C. elegans* paralogous genes [*lipl-1* to *lipl-8*]. We therefore used an unregulated gene expression approach to study the metabolic function of *lipl-4*. We constructed transgenic lines in which the expression of *lipl-4* is driven by the strong, constitutively active promoter *ges-1*. In this way, we uncoupled LIPL-4 expression from its normal transcriptional regulation. Animals carrying the *ges-1* promoter::*lipl-4* gene fusion express *lipl-4* only in the pharynx and gut [Supplemental Fig. S1B] at 12 times higher levels than ad libitum-fed nontransgenic sibling animals [Fig. 1B]. In ad libitum-fed conditions, these *ges-1* promoter::*lipl-4* gene fusion-expressing animals show levels of expression of *lipl-4* mRNA that are physiological for fasting worms; for simplicity, we refer to these animals expressing fasting levels of *lipl-4* constitutively as LIPL-4Ox (*lipl-4* overexpression). To uncover the potential curve in Supplemental Figure S2. (**D**) Fasting and LIPL-4Ox lead to an enrichment of ω-6/5 PUFAs. Levels of AA and EPA relative to total FAMEs [Watts and Browse 2002; Van Gilst et al. 2005b] are depicted as the mean percentage ± SEM for wild-type well-fed and 8-h fasted and well-fed young adults (similar results were obtained when compared with nontransgenic siblings) [data not shown]. (**E**) AA and DGLA, but not EPA, promote resistance to starvation. Ten micromolar AA, 20 μM EPA, 10 μM DGLA [concentrations of supplemented fatty acids that lead to levels of incorporation comparable with those observed in LIPL-4Ox animals] [see Supplemental Fig. S3], or an equal volume of 50% ethanol was added, and the percentage of animals alive was determined and presented as in C but using Sytox green to stain dead worms.
contribution of *lipl-4* to energy homeostasis, we tested the ability of LIPL-4Ox animals to resist nutritional stress. LIPL-4Ox animals are resistant to starvation (Fig. 1C; Supplemental Fig. S2), which suggests that *lipl-4* induction is part of a response that improves *C. elegans*’ ability to resist nutritional deprivation. To study the mechanism by which *lipl-4* promotes resistance to starvation, we performed a more detailed lipid profiling of LIPL-4Ox worms. Fatty acid methyl-ester ([FAME]) analysis of lipids isolated from the *lipl-4*-overexpressing strain [Watts and Browse 2002, O’Rourke et al. 2009] revealed an enrichment of arachidonic acid [AA] and eicosapentaenoic acid [EPA], 20-carbon ω-6 and ω-3 fatty acids, respectively [Fig. 1D]. Fasted wild-type animals are enriched in AA, EPA, and di-homo-γ-linoleic acid [DGLA] [Fig. 1D, Van Gilst et al. 2005b], but the function of this physiological response has not been established. Because ω-3/6 PUFA and AA and DGLA supplementation enhances the ability of wild-type animals to resist starvation (Fig. 1E), suggesting that these ω-6 PUFA and AA promote *C. elegans* survival during starvation. In contrast, supplementation with EPA, a similarly absorbable (Supplemental Fig. S3) 20-carbon ω-3 fatty acid, does not improve *C. elegans* resistance to starvation [Fig. 1E], suggesting that AA and its precursor, DGLA, are not simply used as a carbon source.

To investigate the subcellular localization of LIPL-4, we constructed a protein fusion to TagRFP. This LIPL-4::TagRFP protein fusion is observed in cytoplasmic bodies resembling autophagic granules [Supplemental Fig. S4A]. We tested whether LIPL-4 colocalized with active sites of autophagy by simultaneously looking at the localization of LIPL-4::TagRFP and LGG-1::GFP [Melendez et al. 2008]. The coexpression of LIPL-4::TagRFP and the autophagic marker LGG-1 shows that the LIPL-4 red fluorescent bodies do not colocalize with the LGG-1 green autophagic punctae [Supplemental Fig. S4A, insets in the top panel], suggesting that, at least in the conditions tested, LIPL-4 does not reside in active autophagic bodies. However, this experiment revealed that there are more abundant LGG-1 punctae in LIPL-4-overexpressing animals compared with nontransgenic siblings, suggesting that high expression of LIPL-4 activates autophagy [Fig. 2A, Supplemental Figs. S4A,B [for bleed-through and autofluorescence controls], S5]. Our finding that constitutively increased *lipl-4* expression activates autophagy is in agreement with the previous observation that overexpression of *lipl-4* from its own promoter also increases the number of autophagic structures [Lapierre et al. 2011]. Hence, *lipl-4* is induced upon fasting, a nutritional state that activates autophagy, and high expression of *lipl-4* triggers some of the physiological changes of fasting, such as enrichment of ω-6 PUFA and activation of autophagy. In addition, we observed that the supplementation with fasting-enriched ω-6 PUFA increases *C. elegans* resistance to starvation [Fig. 1E]. As autophagy is a major survival mechanism when food is scarce, we hypothesized
that the fasting-enriched ω-6 PUFAs alone might activate autophagy. We found that supplementation with AA and DGLA, but not with EPA, was sufficient to activate autophagy in ad libitum-fed C. elegans (Fig. 2B). AA or DGLA supplementation did not affect C. elegans food consumption (Supplemental Fig. S6), suggesting that ω-6 PUFAs induce cellular responses characteristic of the response to caloric restriction but do not actually induce caloric restriction.

In C. elegans, fat-6 and fat-7 are required for the synthesis of long chain unsaturated fatty acids, and fat-1 is required for the conversion of ω-6 PUFAs to ω-3 PUFAs. Thus, impaired fat-6 and fat-7 function leads to reduced ω-6 PUFA levels, and fat-1 loss of function leads to reduced ω-3 PUFA levels [Watts and Browse 2002; Van Gilst et al. 2005a]. To address whether differences in the ratios of ω-6 to ω-3 PUFAs would determine the levels of autophagy, we tested whether the fat genes affected the basal levels of autophagy in well-fed animals. RNAi inactivation of fat-6, fat-7, or fat-1 did not affect the intensity or the distribution of LGC-1::RFP in well-fed animals [Fig. 2C], suggesting that the effect of ω-6 fatty acids on autophagy is achieved only when their levels relative to fatty acids other than ω-3 fatty acids are above a certain threshold, a condition that cannot be mimicked by inactivating the enzymes responsible for the synthesis of ω-6 fatty acids or their conversion to ω-3 fatty acids. The absence of an autophagy phenotype in the fat-1 RNAi-treated animals, at least in the conditions tested, suggests that it is not the ratio ω-6 to ω-3 that determines the levels of autophagy in worms but does not rule out that ω-3 PUFAs or some of their derivatives could also have an effect on autophagy levels.

**ω-6 PUFAs activate autophagy in mammalian cells**

Dietary supplementation with ω-3/6 PUFAs can improve several human conditions that intriguingly overlap with the pathologies associated with autophagy malfunction [Cao et al. 2000; Suresh and Das 2001; Das 2008; Deckelbaum and Calder 2010; Kuballa and Xavier 2010]. We tested whether human cells would also respond to ω-6 PUFAs by activating autophagy. Supplementation with AA and its precursor, DGLA, but not with EPA, leads to an enrichment of the autophagic marker phosphatidylinositol-phosphate (Cao et al. 2000; Suresh and Das 2001; Das 2008; Deckelbaum and Calder 2010). To directly tested the degradative capacity of the autophagosomal compartment (red DQ-peptide signal) [Klionsky et al. 2008; Vazquez and Colombo 2009]. Active breakdown of DQ-BSA, even in the presence of AA and DGLA, and the overlap between GFP-hLC3B and the red DQ-peptides observed after AA or DGLA treatment show that the enriched GFP-hLC3B punctae are active sites of autophagic breakdown [Fig. 3B, bottom panels]. Finally, inactivation of the essential autophagy gene ATG16L1 impairs the accumulation of GFP-hLC3B punctae (Fig. 3C), further supporting the hypothesis that AA- and DGLA-triggered enrichment of punctate GFP-hLC3B is due to an increase in the autophagic flux in the treated cells and not the inhibition of the post-sequestration steps of the autophagic process. The combination of data from C. elegans and mammalian cells in culture strongly suggests that ω-6 PUFAs can activate autophagy across metazoans.

**ω-6 PUFAs increase C. elegans life span through the activation of autophagy in well-fed conditions**

lip-4 up-regulation is required to extend the life span of germline-deficient C. elegans [Wang et al. 2008], and autophagy is required for life span extension under caloric restriction [Hansen et al. 2008]. Because LIPL-4 overexpression causes increased levels of autophagy, we tested whether autophagy mediates the life span extension triggered by overexpression of LIPL-4. Inactivation of the essential autophagy genes bec-1 (the ortholog of beclin-1, which is required for autophagosome assembly), lgg-1 [the ortholog of Atg-8/MAPLC3, which is incorporated into preautophagosomal membranes], and atg-16.2 (the ortholog of ATG16p/ATG16L1, which localizes to the
Figure 3. ω-6 PUFAs activate autophagy in mammalian cells. (A) AA and DGLA supplementation leads to an increase in LC3II in HeLa cells. Fifty percent confluent cells were treated with 100 μM AA, DGLA, or EPA or mock-treated with an equal volume of 50% ethanol for 24 h. Representative Western blot analysis of endogenous LC3 in supplemented or mock-treated cells is shown, and quantification of LC3II (autophagy-specific form) signal intensity relative to actin from three independent experiments is depicted as mean ± SEM. (B) AA and DGLA activate autophagy in HeLa cells. The top row depicts HeLa cells stably expressing GFP-hLC3B grown in rich culture medium supplemented with 100 μM AA or DGLA or equal volume of ethanol and imaged after 30 h of total treatment. Quantification of GFP-hLC3B punctae is presented in the table below. The second row shows the increase in GFP-hLC3B punctae observed when the lysosomal inhibitors E64d (5 μg/mL) and pepstatin (10 μg/mL) were added to cells pretreated for 24 h with carrier or fatty acids and incubated for another 6 h with the inhibitors. Quantification of GFP-hLC3B punctae is presented in the table below. The third row shows lysosomal breakdown capacity in the presence of fatty acids as revealed by the cleavage and consequent dequenching of 10 μg/mL red DQ-BSA added after a 24-h treatment with fatty acids and incorporated and cleaved for 6 h. The fourth row shows that the GFP-hLC3B and red DQ-peptide signals overlap in the AA- and DGLA-treated cells (merges between the top and third row images are shown). For all experiments, images were taken after 30 h of total treatment. Images are representative from at least three independent experiments. Bars, 20 μm. The table shows GFP-hLC3B punctae quantification and statistical analyses for three independent experiments. Proportion of cells showing more than five GFP-hLC3B punctae $>2$ μm in the presence or absence of the lysosomal inhibitors is shown as percentages of the total number of cells (n) analyzed per treatment. The number of dots $>2$ μm per cell was quantified from at least 10 different fields using SPOT software. P-values relative to mock-treated cells are presented at the bottom of the columns. Protein aggregation control is shown in Supplemental Figure 5A, and p62/SQSTM1 degradation control is shown in Supplemental Figure 5B. (C) AA- and DGLA-triggered activation of autophagy in mouse embryonic fibroblasts (MEFs) is ATG16L1-dependent. The top row shows wild-type MEFs stably expressing GFP-hLC3B grown in rich culture medium supplemented with 100 μM AA or DGLA or equal volume of ethanol and imaged after 24 h of total treatment. The bottom row shows ATG16L1−/− MEFs stably expressing GFP-hLC3B grown in rich culture medium supplemented with 100 μM AA or DGLA or equal volume of ethanol and imaged after 24 h of total treatment.
preautophagosome and is required for autophagy), suppress the life span extension induced by LIPL-4 overexpression [Fig. 4A; Supplemental Table S1A]. Using LIPL-4OX, transgenic lines in which lipl-4 is constitutively expressed at levels normally observed in fasted worms (ges-1 promoter), we showed that the LIPL-4 overexpression-triggered increase in life span is partially suppressed by inactivation of pha-4, a FoxA transcription factor that binds to the promoters of some autophagy genes [Fig. 4B; Supplemental Table S1B; Zhong et al. 2010; Niu et al. 2011]. In contrast, the inactivation of the FoxO transcription factor daf-16, which controls gene expression upon fasting but not autophagy genes in particular, does not suppress the LIPL-4 overexpression longevity

Figure 4. ω-6 PUFAs extend life span through the activation of autophagy. (A) Autophagy contributes to LIPL-4OX longevity. Representative survival curve of LIPL-4OX or control (nontransgenic siblings) incubated at 20°C in OP50 plates and transferred as L4 larvae to vector control or RNAi against core autophagy genes is presented (mean life spans: control = 16.1, LIPL-4OX = 19.0; P = 3.21 × 10⁻⁷). Mean life span and statistical significance of the differences compared with control of an independent experiment are presented in Supplemental Table S1A. (B) The autophagy transcriptional regulator PHA-4 (FoxA), but not the starvation regulator DAF-16 (FoxO), contributes to the LIPL-4OX-extended life span phenotype. Representative survival curve of LIPL-4OX (ges-1 promoter) or nontransgenic siblings (NTS) grown at 20°C in OP50 plates and transferred as L4 larvae to vector control, pha-4, or daf-16 RNAi is presented. Mean life span and statistical significance of the differences compared with control are presented in Supplemental Table S1B. (C) AA and DGLA extend C. elegans life span. Survival curves of worms grown in OP50 plates and transferred as L4 larvae to plates supplemented with ω-3/6 PUFAs or carrier are presented. Worms were incubated at 20°C and transferred every other day to fresh plates containing 10 μM AA, 10 μM DGLA, 20 μM EPA, or an equal volume of carrier until cessation of reproduction. Worms were then transferred every 7 d to maintain the strength of the treatments. Statistical analysis of an independent experiment is presented in Supplemental Table S2A. (D) AA and DGLA extend C. elegans life span through activation of autophagy. Survival curves of worms grown in OP50 plates, transferred as L4 larvae to RNAi plates supplemented with ω-3/6 PUFAs or carrier, and/or treated with RNAi against autophagy genes or vector control are presented. Worms were incubated at 20°C and transferred every other day to fresh control L4440 or RNAi plates containing 10 μM AA, 10 μM DGLA, 20 μM EPA, or an equal volume of carrier until cessation of reproduction. Worms were then transferred every 7 d to maintain the strength of the treatments. Statistical analyses of independent experiments are presented in Supplemental Table S2B.
phenotype (Fig. 4B; Supplemental Table S1B), further supporting the model that LIPL-4 overexpression extends *C. elegans* life span through the activation of autophagy. A similar autophagy-dependent extension of life span by overexpression of LIPL-4 from its own promoter has been observed (Lapière et al. 2011).

We showed that LIPL-4 overexpression leads to an enrichment of AA and DGLA and that these w-6 PUFAs activate autophagy. We tested whether supplementation with these fasting-enriched w-6 PUFAs would phenocopy the increase in life span induced by activation of autophagy (Cuervo 2008, Rubinsztein et al. 2011). Chronic long-term dietary supplementation with AA and DGLA, but not EPA, extends *C. elegans* life span in conditions of food abundance (Fig. 4C,D, Supplemental Table S2A). Furthermore, this life span extension is *bec-1*, *atg-16.2*, and *lgg-1*-dependent (Fig. 4D, Supplemental Table S2B). These results show not only that dietary supplementation with w-6 PUFAs activates a conserved cellular response normally triggered by fasting, but also that long-term administration of w-6 PUFAs can render the beneficial effects of low-caloric intake even in ad libitum feeding conditions, and suggest that these lipid metabolites would act as signals of nutrient scarcity.

Although the LIPL-4Ox construct is expressed only in the digestive tract (*ges-1* or *vha-6* promoters), increased autophagic signal is also observed in the hypodermal seam cells (Figs. 2A, 5C). This observation suggests that w-6 PUFAs might be secreted and able to improve cellular clearance distal from their site of production. Out of the nine predicted lipid-binding proteins (LBPs) in *C. elegans*, four (*lbp-1, lbp-3, lbp-5, and lbp-7*) are transcriptionally up-regulated upon food withdrawal (Fig. 5A), and LIPL-4Ox induces *lbp-3, lbp-5*, and *lbp-8* transcription (Fig. 5B). We tested the effect of inactivating those LBPs that are transcriptionally activated by fasting and LIPL-4 overexpression—namely, *lbp-3 and lbp-5*—on the activation of autophagy induced by LIPL-4 overexpression. *lbp-3* and *lbp-5* reduction of function by RNAi hinders the hypodermal seam cell activation of autophagy (Fig. 5C) and

**Figure 5.** Lipolysis products activate autophagy in *C. elegans* distal from their production site with the contribution of LBPs. **(A)** *C. elegans* genes encoding the lipid transporter LBPs are transcriptionally up-regulated upon fasting. *lbp-1 to lbp-9* mRNA levels of expression in 6-h-fasted wild-type young adults relative to ad libitum-fed animals of the same developmental age are depicted as mean ± SEM of three independent experiments. **(B)** LIPL-4Ox is sufficient to transcriptionally activate the fasting-responsive lipid transporters *lbp-3, lbp-5, and lbp-8*. *lbp-1 to lbp-9* mRNA levels of expression in LIPL-4Ox relative to control (nontransgenic siblings) incubated at 20°C in OP50 plates are presented as mean ± SEM of three independent experiments. **(C)** LBP-3 and LBP-5 facilitate activation of autophagy distal from the LIPL-4 site of expression. Representative images of LGG-1::GFP signal in intestinal and hypodermal seam cells (yellow arrow) of L3–L4 animals overexpressing LIPL-4 only in the digestive tract (*vha-6* promoter), treated or not from the L4 stage of the first generation with RNAi against *lbp-3* and *lbp-5* (50% each), are presented. **(D)** LBP-3 and LBP-5 contribute to the LIPL-4 overexpression extended life span phenotype. Survival curve of LIPL-4Ox or control (nontransgenic siblings) incubated at 20°C in OP50 plates and transferred as L4 larvae to control or *lbp-3/lbp-5* RNAi plates is presented. Worms were incubated at 20°C and transferred every other day to fresh control L4440 or RNAi plates until cessation of reproduction. Worms were then transferred every 7 d to maintain the strength of the treatments. Detailed statistical analysis of an independent experiment is presented in Supplemental Table S3.
Discussion

The link between lipid metabolism and longevity remains obscure. In C. elegans, animals with decreased fat stores (the caloric restriction mutant model eat-2) [Lakowski and Hekimi 1998] or with increased adiposity (the insulin receptor mutant daf-2) [Kimura et al. 1997] can be long-lived. Even in mammals, the connection between adiposity and life span is not clear. Some murine genetic models with extended life span show increased adiposity [Coschigano et al. 2000; Flurkey et al. 2001; Berryman et al. 2004], and food restriction makes genetically obese mice live longer than wild-type animals even though these mice accumulate twice as much fat as wild-type mice fed ad libitum [Harrison et al. 1984], suggesting a complex link between lipid metabolism and life span regulation. Autophagy, a major cellular clearance mechanism that delays aging [Melendez et al. 2003; Cuervo 2008; Hansen et al. 2008; Rubinsztein et al. 2011], also controls lipid metabolism through a specialized form of autophagy named lipophagy, whose genetic or chemical inactivation leads to an increase in cytosolic fat stores [Singh et al. 2009] in mammals. Germline-deficient C. elegans activate the expression of the lipase gene lipl-4 [Wang et al. 2008] and have increased levels of autophagy [Lapierre et al. 2011]. The coordinated and interdependent activation of LIPL-4 and autophagy in germline-deficient worms [glp-1] led to the hypothesis that enhanced LIPL-4-driven lipophagy could explain the glp-1 extended life span phenotype [Lapierre et al. 2011]. However, the following observations make this hypothesis unlikely: (1) Despite having increased LIPL-4 lipase activity and higher levels of autophagy [Lapierre et al. 2011], glp-1 animals accumulate more cytosolic fats than wild-type animals [O’Rourke et al. 2009]. (2) lipl-4-deficient worms show normal cytosolic fat levels in well-fed and fasting conditions [Supplemental Fig. S1A]. (3) LIPL-4 does not localize to the sites of active autophagy [Supplemental Fig. S4A]. (4) LIPL-4 is a neutral lipase [Lapierre et al. 2011], and the lipases breaking down fats through lipophagy are expected to act in the autophagolysosome and consequently be active at low pHs [Czaja and Cuervo 2009]. The alternative hypothesis in which a lipase breakdown product might activate autophagy was also proposed [Lapierre et al. 2011]. Here we show evidence supporting this latter model; specifically, we show that lipl-4 induction leads to an enrichment of ω-6 PUFAs and that ω-6 PUFAs or some of their derivatives act as metabolic signals that activate autophagy and extend C. elegans life span.

Lipids continue to emerge as a class of molecules that affect behavior, growth, and organismal survival, not only because of their energetic value, but also because of their structural and signaling functions [Vrablik and Watts 2012]. In C. elegans, ω-3/6 PUFAs are required for normal development and neural function [Watts et al. 2003; Kahn-Kirby et al. 2004]. Additionally, eicosapentaenoylethanolamide (EPEA) and arachidonoylethanolamide (AEA) promote C. elegans growth, as reduced levels of these N-acylethanolamines (NAEs) are necessary to enter and maintain the dauer state, a starvation-resistant diapause stage [Lucanic et al. 2011]. Here we showed that, opposite to their NAE derivatives [Supplemental Table S4], EPA and AA are enriched in fasted worms and that AA and its precursor, DGLA, promote resistance to starvation. Also different from their NAE derivatives, AA and its precursor, DGLA, extend C. elegans life span in an abundant food regime. NAEs were proposed to act as high nutrient availability signals, and consequently, they promote reproduction and the correlated program of somatic aging. We propose that AA and DGLA or some derivatives of these lipid metabolites act as signals of reduced food availability and consequently trigger a fasting program that extends life span. It would be interesting to determine whether AA and/or DGLA derive from triglycerides or phospholipids. Alternatively, these ω-6 PUFAs might be breakdown products of cardiolipin, an AA-rich lipid whose levels accompany the drop in mitochondrial content observed in fasting C. elegans [El O’Rourke, unpubl.]. The fasting-enriched ω-3/6 PUFAs are precursors and products of the fasting-depleted NAEs. It is fascinating to find that such closely related lipid molecules have opposite effects on organismal survival. We propose that the relative proportion of these lipids or some of their derivatives would signal nutrient abundance or scarcity and in this way would help to coordinate organismal responses that maximize the chances of survival. It would also be of value to investigate whether glp-1 and daf-2 mutants animals, genetic models of extended life span where lipl-4 is constitutively induced, also have elevated levels of AA and DGLA. NAEs were proposed to function by activating a cannabinoid signaling pathway through yet unknown nematode cannabinoid-like receptors and possibly regulating nutrient intake and energy balance as previously shown in mammals [Lucanic et al. 2011]. Here we showed that the mechanism by which ω-6 PUFAs promote survival is by activating autophagy. Autophagy provides nutrients when external sources of energy are not available and mediates the turnover of damaged organelles and long-lived proteins. Therefore, the activation of autophagy that we documented could explain the prosurvival effects of the ω-6 PUFAs AA and DGLA in conditions of food deprivation and food abundance.

LIPL-4 overexpression is sufficient to not only enrich ω-6 PUFAs and activate autophagy, but also transcriptionally activate nutrient-responsive genes [specifically, genes encoding the fatty acid-binding proteins (FABPs) lbp-3 and lbp-5], revealing a direct link between the activity of LIPL-4 and the regulation of the transcriptional programs activated in C. elegans upon nutritional stress. Lipid metabolites may modulate the activity of fatty acid-regulated transcription factors. AA, DGLA, some derivatives of these lipids, or LIPL-4 products yet to be found
could directly control the function of transcription factors such as PPARα/CeNHR-49, SREBP-1/CeSBP-1, or other NHRs. Additionally, we showed data supporting the hypothesis that the LBP s LBP-3 and LBP-5 contribute to the activation of autophagy distally from the tissue where LIPL-4 is expressed. LBP-3 and LBP-5 are required for the full extension of life span observed in LIPL-4-overexpressing worms, suggesting that systemic activation of autophagy is necessary to fully extend C. elegans life span. LBP-3 and LBP-5 are unique FABPs. Unlike most FABPs, LBP-3 has a signal sequence that drives the secretion of the protein into the interstitial space of C. elegans (Plenefisch et al. 2000). LBP-5, on the other hand, has been characterized as an intracellular lipid transporter that binds AA [Xu et al. 2011]. We propose that LIPL-4 activation leads to an enrichment of ω-6 PUFA s, directly or indirectly acting as metabolic signals that communicate a state of alarm to distal tissues and therefore help coordinate molecular and cellular responses that enhance organismal survival in the absence and presence of food.

In humans, dietary supplementation with ω-3/6 PUFA s (fish oils) can reduce the incidence and improve the condition of patients suffering from inflammatory, neurodegenerative, and neoplastic pathologies [Deckelbaum and Calder 2010, Kuballa and Xavier 2010]. The reduction of the pools of proinflammatory molecules, such as AA, is the most accepted mechanism of action for ω-3 PUFA s (Fritsche 2008). However, type 2 diabetes is associated with low levels of AA [Suhr et al. 2010], and the addition of exogenous AA ameliorates diabetes [Suresh and Das 2001]. Additionally, AA supplementation reduces the risk of cardiovascular disease [Harris et al. 2009] and neurodegeneration [Das 2008], suggesting that the beneficial effects of ω-3/6 fatty acids are not only or necessarily mediated by reducing AA levels. On the contrary, these observations seem to indicate that ω-6 long chain fatty acid supplementation can have beneficial effects despite being precursors of proinflammatory molecules. Additionally, modulation of the endocannabinoid system has been shown to mediate some of the beneficial effects of long chain PUFA dietary supplementation, but these studies had been restricted to analyzing the impact of ω-3 PUFA s [Bayette et al. 2009]. Our data show that supplementation with ω-6 PUFA s activates autophagy in human epithelial cells. As in worms, fasted mammals show enrichment in AA in serum, liver, and/or extrahepatic tissues [de Alaniz et al. 1980, Garg et al. 1992, Zhou and Nilsson 1999]. Moreover, unlike wild-type animals, mice deficient for PPARα, a transcription factor that coordinates essential metabolic responses to fasting [Kersten et al. 1999, Leone et al. 1999], are unable to enrich AA upon fasting [Lee et al. 2004]. This result suggests that enrichment of AA or some of its derivatives is part of an essential response to food deprivation that is conserved across metazoa. The mechanism by which cells sense or uptake ω-6 PUFA s and how these lipid metabolites or some derivatives actually activate autophagy remains to be elucidated. ω-6 PUFA-triggered activation of autophagy seems to be additive to treatment of HeLa cells with rapamycin [E J O’Rourke, unpubl.], suggesting that ω-6 fatty acids would activate autophagy through a mammalian TOR (mTOR)-independent mechanism. Several stimuli have been shown to induce autophagy independent of mTOR, all of which reduce intracellular inositol levels [Ravikumar et al. 2010]. It would be interesting to test whether PI3 kinase inhibitors affect the ω-6 PUFA-triggered activation of autophagy.

The malfunctioning of autophagy has been linked to a wide range of pathological conditions, including neurodegenerative diseases, chronic inflammation, infection, and cancer [Kuballa and Xavier 2010]. Several of these pathologies are ameliorated by dietary supplementation with ω-3/6 PUFA s. The overlap between the beneficial effects of activating autophagy and the salubrious effects of ω-3/6 PUFA consumption, together with the data presented here, suggests that ω-3/6 PUFA s could counteract the deterioration of the autophagic system normally occurring during aging. Our data suggest that ω3/6 PUFA s could be used, and/or analogs could be developed, to activate or even inhibit autophagy, both of which would be of great help in the prevention and treatment of multiple pathologies.

Materials and methods

C. elegans strains

lipl-4(tm4417) was backcrossed four times. LIPL-4::TagRFP corresponds to EJvha-6F::lipl-4 ORF::TagRFP [three independent lines]. LIPL-4Ox corresponds to EJges-1P::lipl-4ORF::SL2::GFP [two independent lines]. These animals with constitutive fasting levels of expression of lipl-4 [several independent lines and two different constructs] are developmentally delayed, so animals were synchronized based on vulva and/or gonadal development and not chronological age. LGG-1::GFP from DA2123 [Kang et al. 2007] was crossed to LIPL-4::TagRFP.

Transcriptional analyses

Young adults (adult vulva with less than five eggs) were harvested and washed in a 35-μm nylon mesh. For fasting experiments, animals were seeded back onto empty NGM plates (fasting) or back onto OP50 plates (well-fed control). After the fasting period, treated and controls were harvested, washed in a 35-μm nylon mesh, and frozen in liquid nitrogen. Total RNA was isolated using TRIzol (Molecular Research Center, Inc.), and RT–PCR was performed as previously described [Troemel et al. 2006]. Data presented are from at least three independent experiments, and all values are corrected for the efficiency of the primer pairs and normalized to ams-1 as internal control as well as to transcript levels in same age untreated, wild-type, or nontransgenic sibling animals. All quantitative RT–PCR [qRT–PCR] reactions were performed at least in triplicate. Median ± SEM of ΔΔCt is reported [Pfaffl 2001].

FAME analysis

LIPL-4Ox transgenic hatchlings were selected based on fluorescent signal with a COPAS Biosort and seeded on OP50 plates 6 h earlier than their nontransgenic siblings, and all strains were incubated at 20°C. FAMEs were extracted from young fertile adults as previously reported [Watts and Browse 2002] with
modifications. Lipids from an equal number of worms [see the Supplemental Material] were extracted with chloroform:methanol 2:1. FAMEs were generated by incubating in 5% sulfuric acid in methanol for 1 h at 80°C. FAMEs were resuspended in hexane and run in a C20 wax Supelco column. Methyl-fatty acid standards were run to determine retention times. The area under the peaks for the methyl-fatty acids of interest is presented as average percentage of total FAMEs from three independent experiments ± SD.

Survival resistance
LIPL-4Ox transgenic hatchlings were selected based on fluorescent signal with a COPAS Biosort (Union Biometrica). LIPL-4Ox animals were seeded on OP50 plates 6 h earlier than their non-transgenic siblings. For all starvation resistance experiments, animals were incubated at 20°C. Approximately 10,000 young L4s were harvested for each strain or treatment and extensively washed through a 20-μm mesh. Larvae were resuspended in 10 mL of S-basal, to which we added 2.5 μL of 5 mM Sytox green or red (Molecular Probes) and, when indicated, 10 μM AA (Cayman, catalog no. 90010), 10 μM DGLA (Cayman, catalog no. 90230), or 20 μM EPA (Cayman, catalog no. 90110) or equal volume of carrier (50% ethanol). The worm suspensions were maintained by rocking at 20°C. Approximately 500 worms were run through a Biosort at the indicated times. Animals with TOF [time of flight] between 100 and 500 (arbitrary units) and EXT (extinction) between 60 and 300 (arbitrary units) were analyzed. Animals with green fluorescent signal ≥50 or red signal ≥25 were dead, as established by lack of movement in a liquid drop. Percent survival = [1 − (worms with green or red signal ≥50 or 25/total worms)] × 100. Survival estimates were not necessarily monotonically decreasing, since random samples of each population were taken at each time point. When worms were sampled to determine survival, some number of worms died before the point of sampling, but time of death is unknown. Consequently, our data are left censored. Traditional Kaplan-Meier analysis of survival could not be performed with this experimental setup. Instead, we compared the median and standard deviations at the time point when wild-type untreated worm populations were closest to 50% alive and performed t-test analysis to compare the percentage of animals alive at that particular time point.

Longevity
Wild-type, transgenic [multiple lines], or nontransgenic sibling L4 larvae, selected based on fluorescent signal, were transferred in duplicate to sextuplicate [50–150 total worms] to fresh NGM L4s were harvested for each strain or treatment and extensively washed through a 20-μm mesh. Larvae were resuspended in 10 mL of S-basal, to which we added 2.5 μL of 5 mM Sytox green or red (Molecular Probes) and, when indicated, 10 μM AA (Cayman, catalog no. 90010), 10 μM DGLA (Cayman, catalog no. 90230), or 20 μM EPA (Cayman, catalog no. 90110) or equal volume of carrier (50% ethanol). The worm suspensions were maintained by rocking at 20°C. Approximately 500 worms were run through a Biosort at the indicated times. Animals with TOF [time of flight] between 100 and 500 (arbitrary units) and EXT (extinction) between 60 and 300 (arbitrary units) were analyzed. Animals with green fluorescent signal ≥50 or red signal ≥25 were dead, as established by lack of movement in a liquid drop. Percent survival = [1 − (worms with green or red signal ≥50 or 25/total worms)] × 100. Survival estimates were not necessarily monotonically decreasing, since random samples of each population were taken at each time point. When worms were sampled to determine survival, some number of worms died before the point of sampling, but time of death is unknown. Consequently, our data are left censored. Traditional Kaplan-Meier analysis of survival could not be performed with this experimental setup. Instead, we compared the median and standard deviations at the time point when wild-type untreated worm populations were closest to 50% alive and performed t-test analysis to compare the percentage of animals alive at that particular time point.

Autophagy assessment
LIPL-4::TagRFP, LGG-1::GFP transgenic hatchlings were separated from their LGG-1::GFP-only siblings based on fluorescent signal with a COPAS Biosort and then seeded on OP50 plates. LIPL-4::TagRFP, LGG-1::GFP animals were seeded 6 h earlier than worms carrying only LGG-1::GFP. Animals were harvested as L3–L4 larvae, immobilized with 2,3-Butanedione monoxamine (30 mg/mL Sigma-Aldrich) for 10 min, mounted, and documented. For supplementation experiments, LGG-1::GFP hatchlings were seeded in plates containing 50 μM fatty acids or equal volume of 50% ethanol. Mock or supplemented animals were harvested as L3–L4 larvae and treated for documentation as described above. No “autophagic flux” assay or reporter has been described for C. elegans (Klionsky et al. 2008).

For Western-blotting, HeLa cells were grown in complete IMDM medium [Invitrogen] containing 10% fetal bovine serum and supplemented with 100 μM a3/6 fatty acids or equal volume of ethanol. [Note: Effective concentration of the fatty acids is unclear given the capacity of LBPs in the serum to sequester fatty acids.] Cells were harvested after 16, 24, or 30 h of treatment and immediately frozen for later processing.

HeLa cells and ATG16L1-proficient and ATG16L1-deficient mouse embryonic fibroblasts (RJ Xavier and HW Virgin, in prep.) stably expressing GFP-hLC3B fusion proteins were generated as described before (Kuballa et al. 2008). Inactive LC3 mutant, GFP-hLC3B-G120A, lentiviral construct was generated by site-directed mutagenesis and transduced at least three passages before the first experiment was made. For quantification of GFP-hLC3B puncta, cells were grown in culture-rich medium [complete IMDM medium containing 10% fetal bovine serum], supplemented with 100 μM AA, DGLA, or equal volume of ethanol, and monitored using direct fluorescence microscopy. For inhibitor and substrate degradation experiments monitored by immunoblotting, 5 μg/mL E64d [Sigma] and 10 μg/mL pepstatin [Sigma] were added after 10 h of treatment with fatty acids, and samples were harvested and frozen at 16 h of total treatment [a time point within the dynamic range of LC3II signal]. For inhibitor or substrate degradation experiments monitored by direct fluorescence microscopy, 5 μg/mL E64d [Sigma] and 10 μg/mL pepstatin [Sigma] and/or 10 μg/mL DQ-BSA [Molecular Probes] were added after 24 h of treatment with fatty acids, and images were taken after 30 h of total treatment [a time point within the dynamic range of large punctae formation; for AA plus inhibitors, saturation was reached at 48 h of treatment] using a Nikon Eclipse TE2000-S microscope; the number of dots >2 μm per cell was quantified from at least 10 different fields using SPOT software [Diagnostics Instruments, Inc.].

Acknowledgments
We thank members of the Ruvkun, Ausubel, and Kaplan laboratories for helpful comments, especially A. Lee-Conery for help with longevity experiments; J. Larkins-Ford for performing Biosort analyses; J. Rapley, J. Avrutich, R. Niedra, and B. Seed for sharing expertise and reagents for mammalian experiments; and H.Y. Mak, A. Soukas, M. Van Gilst, M. Freeman, A. Saghatelian, and C. Tyler for protocols, access to equipment, and discussions on lipid measurements. We thank Dr. Mitani and the National Bioresource Project for strains. We also thank C. Danna for helpful suggestions and comments on the manuscript. This work was supported by grants R01DK070147 [to G.R.] and K99DK087928 [to E.J.O’R.]. E.J.O’R. designed the overall studies, performed the experiments, and wrote the manuscript. G.R. revised the manuscript. P.K. and R.X. provided GFP-hLC3B and GFP-hLC3B-G120A HeLa cells and ATG16L1-proficient and ATG16L1-deficient mouse embryonic fibroblasts and revised the manuscript.

References
Apfeld J, O’Connor G, McDonagh T, DiStefano PS, Curtis R. 2004. The AMP-activated protein kinase AAK-2 links energy levels and insulin-like signals to lifespan in C. elegans. Genes Dev 18: 3004–3009.
Bass TM, Weinkove D, Houthoofd K, Gems D, Partridge L. 2007. Effects of resveratrol on lifespan in *Drosophila melanogaster* and *Caenorhabditis elegans*. Mech Ageing Dev 128: 546–552.

Battetta B, Grinian M, Carta G, Murru E, Ligresti A, Cordeddu L, Giordano E, Sanna F, Bisogno T, Uda S, et al. 2009. Endo-cannabinoids may mediate the ability of [n-3] fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. *J Nutr* 139: 1495–1501.

Berdichevsky A, Viswanathan M, Horvitz HR, Guarente L. 2006. *C. elegans* SIR-2.1 interacts with 14-3-3 proteins to activate DAF-16 and extend life span. *Cell* 125: 1165–1177.

Berryman DE, List EO, Coschigano KT, Behar K, Kim JK, Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, Cao Y, Pearman AT, Zimmerman GA, McIntyre TM, Prescott de Alaniz MJ, de Gomez Dumm IN, Brenner RR. 1980. Effect of *n*-3 fatty acids on the severity of radiation-induced proctitis. *Proc Natl Acad Sci U S A* 77: 7296–7300.

Berryman DE, List EO, Coschigano KT, Behar K, Kim JK, Kopchick JJ. 2004. Comparing adiposity profiles in three mouse models with altered GH signaling. *Growth Horm IGF Res* 14: 309–318.

Cao Y, Pearman AT, Zimmerman GA, McIntyre TM, Prescott SM. 2000. Intracellular unesterified arachidonic acid signals apoptosis. *Proc Natl Acad Sci U S A* 97: 11280–11285.

Coschigano KT, Clemmons D, Bellush LL, Kopchick JJ. 2000. Assessment of growth parameters and life span of GH/BP gene-disrupted mice. *Endocrinology* 141: 2608–2613.

Cuervo AM. 2008. Autophagy and aging: Keeping that old broom working. *Trends Genet* 24: 604–612.

Czaia MJ, Cuervo AM. 2009. Lipases in lysosomes, what for? *Autophagy* 5: 866–867.

Das UN. 2008. Folic acid and polyunsaturated fatty acids improve cognitive function and prevent depression, dementia, and Alzheimer's disease—but how and why? *Prostaglandins Leukot Essent Fatty Acids* 79: 117–124.

Dekelbaum RJ, Calder PC. 2010. Dietary n-3 and n-6 fatty acids: Are there 'bad' polyunsaturated fatty acids? *Curr Opin Clin Nutr Metab Care* 13: 123–124.

Das UN, Johnston MM, Morgan AG, Williams KE. 2004. The role of dietary fatty acids in brain function. *Lipids* 39: 523–548.

Flurkey K, Papaconstantinou I, Miller RA, Harrison DE. 2001. Assessment of growth parameters and life span of transgenic *C. elegans* overexpressing the insulin receptor-like gene that regulates longevity and diabetes. *Proc Natl Acad Sci U S A* 98: 7723–7728.

Garg ML, Keelan M, Thomson AB, Clandinin MT. 1992. Requirement of PPARs in maintaining phospholipid metabolism. *J Lipid Res* 33: 1495–1501.

Gibson BW, Lithgow GJ, Gill MS. 2011. N-acylethanolamine-dependent sensory signaling in vivo. *Cell Metab* 14: 1165–1177.

Hansen M, Chandra A, M Kristensen N, Bangsbo J, Vang A, Poulsen T, et al. 2000. Inhibition of proliferation and cyclin expression in human colon cancer cells by fatty acids. *Biochim Biophys Acta* 1507: 17–25.

Hansen M, Chandra A, M Kristensen N, Bangsbo J, Vang A, Poulsen T, et al. 2000. Inhibition of proliferation and cyclin expression in human colon cancer cells by fatty acids. *Biochim Biophys Acta* 1507: 17–25.

Hansen M, Chandra A, M Kristensen N, Bangsbo J, Vang A, Poulsen T, et al. 2000. Inhibition of proliferation and cyclin expression in human colon cancer cells by fatty acids. *Biochim Biophys Acta* 1507: 17–25.

Hansen M, Chandra A, M Kristensen N, Bangsbo J, Vang A, Poulsen T, et al. 2000. Inhibition of proliferation and cyclin expression in human colon cancer cells by fatty acids. *Biochim Biophys Acta* 1507: 17–25.

Hansen M, Chandra A, M Kristensen N, Bangsbo J, Vang A, Poulsen T, et al. 2000. Inhibition of proliferation and cyclin expression in human colon cancer cells by fatty acids. *Biochim Biophys Acta* 1507: 17–25.

Hansen M, Chandra A, M Kristensen N, Bangsbo J, Vang A, Poulsen T, et al. 2000. Inhibition of proliferation and cyclin expression in human colon cancer cells by fatty acids. *Biochim Biophys Acta* 1507: 17–25.

Hansen M, Chandra A, M Kristensen N, Bangsbo J, Vang A, Poulsen T, et al. 2000. Inhibition of proliferation and cyclin expression in human colon cancer cells by fatty acids. *Biochim Biophys Acta* 1507: 17–25.

Hansen M, Chandra A, M Kristensen N, Bangsbo J, Vang A, Poulsen T, et al. 2000. Inhibition of proliferation and cyclin expression in human colon cancer cells by fatty acids. *Biochim Biophys Acta* 1507: 17–25.

Hansen M, Chandra A, M Kristensen N, Bangsbo J, Vang A, Poulsen T, et al. 2000. Inhibition of proliferation and cyclin expression in human colon cancer cells by fatty acids. *Biochim Biophys Acta* 1507: 17–25.

Hansen M, Chandra A, M Kristensen N, Bangsbo J, Vang A, Poulsen T, et al. 2000. Inhibition of proliferation and cyclin expression in human colon cancer cells by fatty acids. *Biochim Biophys Acta* 1507: 17–25.

Hansen M, Chandra A, M Kristensen N, Bangsbo J, Vang A, Poulsen T, et al. 2000. Inhibition of proliferation and cyclin expression in human colon cancer cells by fatty acids. *Biochim Biophys Acta* 1507: 17–25.

Hansen M, Chandra A, M Kristensen N, Bangsbo J, Vang A, Poulsen T, et al. 2000. Inhibition of proliferation and cyclin expression in human colon cancer cells by fatty acids. *Biochim Biophys Acta* 1507: 17–25.

Hansen M, Chandra A, M Kristensen N, Bangsbo J, Vang A, Poulsen T, et al. 2000. Inhibition of proliferation and cyclin expression in human colon cancer cells by fatty acids. *Biochim Biophys Acta* 1507: 17–25.

Hansen M, Chandra A, M Kristensen N, Bangsbo J, Vang A, Poulsen T, et al. 2000. Inhibition of proliferation and cyclin expression in human colon cancer cells by fatty acids. *Biochim Biophys Acta* 1507: 17–25.

Hansen M, Chandra A, M Kristensen N, Bangsbo J, Vang A, Poulsen T, et al. 2000. Inhibition of proliferation and cyclin expression in human colon cancer cells by fatty acids. *Biochim Biophys Acta* 1507: 17–25.
Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 66: 191–201.

Mizushima N, Yoshimori T. 2007. How to interpret LC3 immunoblotting. Autophagy 3: 542–545.

Niu W, Lu ZJ, Zhong M, Sarov M, Murray JJ, Bredlik CM, Janette J, Chen C, Alves P, Preston E, et al. 2011. In silico transcription factor binding features revealed by genome-wide ChIP-seq in C. elegans. Genome Res 21: 245–254.

O’Rourke EJ, Soukas AA, Carr CE, Ruvkun G. 2009. Fat metabolism links germline stem cells and longevity in C. elegans. Science 322: 957–960.

Watts JL, Browse J. 2002. Genetic dissection of polyunsaturated fatty acid synthesis in Caenorhabditis elegans. Proc Natl Acad Sci 99: 5854–5859.

Watts JL, Phillips E, Grifﬁng KR, Browse J. 2003. Deﬁciencies in C20 polyunsaturated fatty acids cause behavioral and developmental defects in Caenorhabditis elegans fat-3 mutants. Genetics 163: 581–589.

Xu M, Joo HJ, Paik YK. 2011. Novel functions of lipid-binding protein 5 in Caenorhabditis elegans fat metabolism. J Biol Chem 286: 28111–28118.

Zhong M, Niu W, Lu ZJ, Sarov M, Murray JJ, Janette J, Raha D, Sheaffer KL, Lam HY, Preston E, et al. 2010. Genome-wide identiﬁcation of binding sites deﬁnes distinct functions for Caenorhabditis elegans PHA-4/FOXA in development and environmental response. PLoS Genet 6: e1000848.

Zhou L, Nilsson A. 1999. Fasting increases tissue uptake and interconversion of plasma unesteriﬁed linoleic acid in guinea pigs. Biochim Biophys Acta 1436: 499–508.

Zinke I, Schutz CS, Katzenberger JD, Bauer M, Pankratz MJ. 2002. Nutrient control of gene expression in Drosophila: Microarray analysis of starvation and sugar-dependent response. EMBO J 21: 6162–6173.